Business Wire

Inotrem Announces Positive Results From the Phase IIa Study of Its Lead Compound, Nangibotide (LR12), in the Treatment of Septic Shock

Del

Inotrem S.A., a biotechnology focused on the modulation of the TREM pathway for the management of inflammatory syndromes, announced positive results for its Phase IIa study that demonstrated the safety and tolerability of its lead product candidate, nangibotide (LR12), in septic shock patients. The results were presented today at the annual congress of the International Sepsis Forum in Bangkok.

Septic shock is the ultimate complication of sepsis and currently constitutes an unmet medical need. The incidence of septic shock continuously raises and mortality remains elevated (35%) in developed countries. There is currently no specific therapy approved for this indication besides antibiotics and symptomatic agents, and Inotrem’s solution has the potential to become the first mechanism-based treatment for septic shock. Nangibotide is developed by Inotrem and is based on a novel approach of immunomodulation: it specifically targets the TREM-1 pathway which is crucial mediator of the septic shock.

The reported study was an 11-months multicenter phase IIa clinical trial with 49 patients suffering from septic shock enrolled in four European countries (Belgium, France, The Netherlands and Spain). The results bring positive data on the safety and tolerability of Inotrem’s lead product candidate, nangibotide, in septic shock patients. The study also showed that nangibotide treatment provided consistent trends in a more favorable evolution of biological and clinical activity markers in the subgroup of patients with soluble TREM-1 levels above median at entry. These results support Inotrem’s personalized medicine approach: using soluble TREM-1 level in blood as a potential biomarker for the identification of patients who will most likely benefit from nangibotide treatment. The results from this clinical trial reinforce previous preclinical and clinical findings, in particular about the safety, biological and clinical activity of nangibotide and the use of sTREM-1 as a companion biomarker for patient selection. Consequently, the company intends to launch in 2019 a Phase IIb study, with the aim to bring a strong proof of clinical activity of nangibotide in septic shock patients.

Jean-Jacques Garaud, CEO of Inotrem said: “These results are very encouraging for septic shock patients and confirms the therapeutic potential of our novel personalized approach based on immunomodulation targeting the TREM-1 pathway.”

Bruno François, MD, from the Limoges University Hospital, Coordinating Investigator of the study, added: “These positive data open promising and interesting prospects on a severe and often life-threatening disease, that currently has no approved targeted therapy”.

Inotrem previously announced it was granted access to EMA’s priority medicines scheme (PRIME) for its lead compound nangibotide (LR12) in the treatment of septic shock. In parallel, Inotrem is developing in partnership with Roche Diagnostics a quantitative assay for the biomarker sTREM-1, paving the way to a personalized healthcare approach in critical care medicine.

For more information about Inotrem’s Phase 2a study, please refer to the abstract published in Intensive Care Medicine Experimental: Safety and pharmacodynamic activity of a novel TREM-1 pathway inhibitory peptide in septic shock patients phase IIa clinical trial results, Bruno François et al, Intensive Care Medicine Experimental 2018, 6(Suppl 1): P1.

About Inotrem
Inotrem S.A. is a biotechnology company specialized in for the control of acute inflammatory syndromes, such as septic shock. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, LR12 (nangibotide), with applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. Inotrem is supported by leading European investors — Sofinnova Partners, Andera Partners (previously Edmond de Rothschild Investment Partners), Biomed Invest and Inserm Transfert Initiative.
www.inotrem.com

Contact information

Media contact for Inotrem
S&I
Anne REIN, +33 6 03 35 92 05
anne.rein@strategiesimage.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Manifesto: Call for a Successful Transition to Renewables in the Transportation Sector21.11.2018 13:04Pressemelding

Political course corrections, coupled with the alarming reports on climate conservation, have led the organizers behind Power2Drive and other endorsers to initiate a manifesto. The aim is to deepen the close connection between e-mobility and renewable sources of energy and achieve a sustainable future. The smarter E Europe, the largest energy industry platform in Europe, will demonstrate the potential held by this combination of mobility and clean energy, and the pressing need to pay greater attention to sector coupling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181121005307/en/ Survey shows: Solar power for refuelling is popular (© Solar Promotion GmbH & Bundesverband Solarwirtschaft e.V. BSW) The organizers behind Power2Drive have formed a strong alliance committed to the idea of a successful transition to renewable sources of energy in the transportation sector. Some of the declaration’s first signatories include the

Knopp Biosciences to Present at the Piper Jaffray 30th Annual Healthcare Conference21.11.2018 11:00Pressemelding

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today announced that management will present at the Piper Jaffray 30th Annual Healthcare Conference to be held in New York, NY on November 27-29. Michael Bozik, M.D., President and CEO of Knopp Biosciences, is scheduled to present on Tuesday, November 27th at 12:50 p.m. Eastern Time. ABOUT KNOPP BIOSCIENCES LLC Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need. Knopp’s clinical-stage small molecule, dexpramipexole, is entering Phase 3 clinical studies in hypereosinophilic syndrome and Phase 2 clinical studies in eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, ti

REPLY: Syskoplan Reply Awarded with the SAP Quality Award in the Innovation Category21.11.2018 09:00Pressemelding

Syskoplan Reply, the SAP technology specialist within the Reply Group, has been awarded with the SAP Quality Award from SAP in the Innovation category for a project for the SEA Group. The award honors the latest SAP solutions and it is presented annually at the SAP NOW event. Syskoplan Reply receives the renowned award for the fifth time in a row. The gold award winning project is an innovative SAP Hybris Marketing solution for SEA from Syskoplan Reply. The SEA Group manages both Milan Linate and Milan Malpensa airports and provides all services and related activities. The project consists of implementing SAP Hybris Marketing to design, create and monitor marketing initiatives. The aim is to increase the customer experience of passengers at Milan Malpensa Airport and make their stay a special experience. The cross-departmental, effective marketing campaign is based on the concept of gamification: in the multi-channel campaign, passengers can participate in a treasure hunt "Hashtag Hunt

GSMA Launches New Industry-Wide Initiative to Support Development of Operator Edge Cloud AR/VR21.11.2018 09:00Pressemelding

The GSMA today announced the launch of a new industry-wide initiative called The GSMA Cloud AR/VR Forum that will focus on the development of cloud virtual reality (VR) and augmented reality (AR) technology. The programme which was unveiled at Huawei’s 9th Global Mobile Broadband Forum in London, is backed by mobile operators including China Mobile, China Telecom, China Unicom, Deutsche Telekom, KDDI, KT Corp., NTT DOCOMO, SK Telecom, Telefónica, Telenor, TIM, Turkcell and Vodafone, as well as other industry partners including Huawei and HTC. The programme aims to encourage all parties to collaborate on accelerating the delivery and deployment of 5G cloud-based AR/VR services. “Both VR and AR are disruptive forms of immersive multimedia that, combined with operator edge cloud and 5G connectivity, will transform the cost structures of the enterprise and entertainment fields,” commented Alex Sinclair, Chief Technology Officer, GSMA. “Mobile operators will play a key role in its developme

Clientron to exhibit its embedded computing innovations at SPS IPC Drives 201821.11.2018 09:00Pressemelding

Clientron Corp., a world-leading supplier of embedded systems, will introduce its intelligent embedded solutions including single board computers, embedded box PC, and industrial panel PC at SPS IPC Drives 2018, taking place at the Exhibition Centre Nuremberg (No.8-512, Hall 8) from 27 to 29 November in Nuremberg, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181121005002/en/ Clientron to exhibit its brand new intelligent embedded systems at SPS IPC Drives 2018 (Photo: Business Wire) The SPS IPC Drives is the leading trade fair for electronic automation solutions. At the show, Clientron will proud to illustrate its embedded computing solutions for factory automation and food industry applications. The advantages of Clientron’s products are designed for high quality, durability, flexibility and maximum compatibility to facilitate the business transformation towards Industry 4.0. During the show, Clientron will intro

Wireless charging makes a world’s first debut on South Western Railway trains in the UK.21.11.2018 09:00Pressemelding

Baker Bellfield, one of the UK’s leading suppliers of commercial interior solutions for the rail sector, and Aircharge, global leader in wireless charging solutions for contract use, have announced today the launch of the world’s first fully rail compliant inductive phone wireless charging system. On-train wireless charging will debut on South Western Railway’s (SWR) refurbished and reconfigured class 444 Siemens Desiro five-car EMUs on the London Waterloo – Southampton – Bournmouth – Weymouth route from November 2018. When the refurbishment programme is completed, all 172 of SWR Desiro class trains will have this new feature. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181121005180/en/ The Aircharge - Baker Bellfield mobile phone wireless charging solution for trains (Photo: Business Wire) With mobile devices becoming the best travel companions for personal and business purposes, including the use of mobile check-in appl